Patents Assigned to CV Therapeutics, Inc.
-
Patent number: 7317017Abstract: Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.Type: GrantFiled: July 25, 2005Date of Patent: January 8, 2008Assignee: CV Therapeutics, Inc.Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
-
Patent number: 7304070Abstract: Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.Type: GrantFiled: September 16, 2004Date of Patent: December 4, 2007Assignee: CV Therapeutics, Inc.Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
-
Patent number: 7300923Abstract: Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: August 29, 2005Date of Patent: November 27, 2007Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Michael Organ, Yaroslav Bilokin, Stanislas Mayer, Anthony Disanti, Scott Miller, Peter Kernast
-
Patent number: 7271157Abstract: Disclosed is a synthesis suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonist having the structure of Formula I: wherein R is optionally substituted phenyl, that are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: June 30, 2005Date of Patent: September 18, 2007Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Jeff Zablocki
-
Patent number: 7271169Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: September 7, 2005Date of Patent: September 18, 2007Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Dmitry Koltun
-
Patent number: 7262198Abstract: Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.Type: GrantFiled: June 13, 2006Date of Patent: August 28, 2007Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Kenneth Rehder, Jeff Zablocki
-
Patent number: 7262176Abstract: Disclosed are novel compounds that are A3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.Type: GrantFiled: November 25, 2003Date of Patent: August 28, 2007Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Patent number: 7238700Abstract: Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is optionally substituted alkyl or a group —Y-Z, in which Y is a covalent bond or optionally substituted alkylene, and Z is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkenyl or optionally substituted alkynyl, with the proviso that when Y is a covalent bond Z cannot be alkenyl or alkynyl; and X is oxygen, sulfur, or NH—, or a pharmaceutically acceptable salt, ester, or prodrug thereof. The compounds are particularly useful for treating asthma and diabetic retinopathy.Type: GrantFiled: April 30, 2004Date of Patent: July 3, 2007Assignee: CV Therapeutics, Inc.Inventors: Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki, Dengming Xiao
-
Patent number: 7208496Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: June 7, 2004Date of Patent: April 24, 2007Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih Elzein, Tim Marquart
-
Patent number: 7205303Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, m particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.Type: GrantFiled: December 19, 2003Date of Patent: April 17, 2007Assignee: CV Therapeutics, Inc.Inventors: Venkata Palle, Jeff Zablocki
-
Patent number: 7189730Abstract: Disclosed are novel A2A adenosine receptor antagonists of the formula: wherein: R1 is optionally substituted aryl or optionally substituted heteroaryl; R2 is optionally substituted lower alkyl or optionally substituted cycloalkyl; R3 is hydrogen, halogen, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; X is —O—, —S—, or —NH—; and Y is optionally substituted alkylene; and the pharmaceutically acceptable salts thereof; which are useful for treating various disease states, for example cardiovascular disorders, including tissue damage due to ischemia, CNS diseases, including Parkinson's disease, depression, and the like.Type: GrantFiled: December 18, 2002Date of Patent: March 13, 2007Assignee: CV Therapeutics, Inc.Inventor: Gloria Cristalli
-
Patent number: 7183264Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.Type: GrantFiled: August 29, 2003Date of Patent: February 27, 2007Assignee: CV Therapeutics, Inc.Inventors: Jeff Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
-
Patent number: 7163928Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: February 2, 2004Date of Patent: January 16, 2007Assignee: CV Therapeutics, Inc.Inventors: Gloria Cristalli, Venkata Palle, Jeff Zablocki
-
Patent number: 7160592Abstract: Coatings are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one layer of a polyester on the bonded lactone. Biologically active agents may be deposited with the polyester layers. Such coated surfaces may be useful in medical devices, in particular stents.Type: GrantFiled: February 14, 2003Date of Patent: January 9, 2007Assignee: CV Therapeutics, Inc.Inventors: Frantisek Rypacek, Monika Lapcikova, Ludka Machova
-
Patent number: 7157440Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: May 27, 2004Date of Patent: January 2, 2007Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Patent number: 7144871Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.Type: GrantFiled: February 19, 2003Date of Patent: December 5, 2006Assignee: CV Therapeutics, Inc.Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
-
Patent number: 7144872Abstract: This specification discloses 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: October 18, 2005Date of Patent: December 5, 2006Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
-
Patent number: 7125876Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useflul in the treatment of diabetes.Type: GrantFiled: December 5, 2003Date of Patent: October 24, 2006Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Dmitry Koltun, Jeff Zablocki
-
Patent number: 7125993Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, having the structure of Formula I or Formula II: by cyclizing a compound of the formula (3):Type: GrantFiled: November 21, 2003Date of Patent: October 24, 2006Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
-
Patent number: 7115610Abstract: Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.Type: GrantFiled: December 17, 2004Date of Patent: October 3, 2006Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Kenneth Rehder, Jeffrey Zablocki